Selected baseline characteristics
| Characteristic . | Participants (N = 32) . |
|---|---|
| Age at WM diagnosis, median (range), y | 58 (38-72) |
| Age at venetoclax initiation, median (range), y | 66 (39-80) |
| Male sex, n (%) | 18 (56) |
| Serum IgM level, median (range), mg/dL | 3512 (642-7970) |
| Hemoglobin level, median (range), g/dL | 10.6 (6.4-13.5) |
| Platelet count, median (range), ×103/μL | 216 (60-445) |
| Serum β2-microglobulin level, median (range), mg/L | 3.6 (1.9-9.8) |
| Low IPSSWM score, n (%) | 12 (38) |
| Intermediate IPSSWM score, n (%) | 8 (25) |
| High IPSSWM score, n (%) | 12 (38) |
| Bone marrow involvement, median (range), % | 35 (4-90) |
| Adenopathy ≥1.5 cm, n (%) | 9 (28) |
| Splenomegaly ≥15 cm, n (%) | 8 (25) |
| MYD88 L265P mutation, n (%) | 32 (100) |
| CXCR4 mutation, n (%) | 17 (53) |
| No. of previous therapies, median (range) | 2 (1-10) |
| Previous anti-CD20 therapy, n (%) | 28 (88) |
| Previous BTK inhibitor, n (%) | 16 (50) |
| Characteristic . | Participants (N = 32) . |
|---|---|
| Age at WM diagnosis, median (range), y | 58 (38-72) |
| Age at venetoclax initiation, median (range), y | 66 (39-80) |
| Male sex, n (%) | 18 (56) |
| Serum IgM level, median (range), mg/dL | 3512 (642-7970) |
| Hemoglobin level, median (range), g/dL | 10.6 (6.4-13.5) |
| Platelet count, median (range), ×103/μL | 216 (60-445) |
| Serum β2-microglobulin level, median (range), mg/L | 3.6 (1.9-9.8) |
| Low IPSSWM score, n (%) | 12 (38) |
| Intermediate IPSSWM score, n (%) | 8 (25) |
| High IPSSWM score, n (%) | 12 (38) |
| Bone marrow involvement, median (range), % | 35 (4-90) |
| Adenopathy ≥1.5 cm, n (%) | 9 (28) |
| Splenomegaly ≥15 cm, n (%) | 8 (25) |
| MYD88 L265P mutation, n (%) | 32 (100) |
| CXCR4 mutation, n (%) | 17 (53) |
| No. of previous therapies, median (range) | 2 (1-10) |
| Previous anti-CD20 therapy, n (%) | 28 (88) |
| Previous BTK inhibitor, n (%) | 16 (50) |
IgM, immunoglobulin M; IPSSWM, International Prognostic Scoring for WM.